Clinical trial NCT01980160 - References

Nausea — Relief Band as an Adjunct to Antiemetic Therapy in Patients Who Receive Mod to Highly Emetogenic Chemotherapy

Citation(s)

•   Birch R, Weaver CH, Carson K, Buckner CD
  A randomized trial of once vs twice daily administration of intravenous granisetron with dexamethosone in patients receiving high-dose cyclophosphamide, thiotepa and carboplatin. Bone Marrow Transplant. 1998 Oct;22(7):685-8.
•   Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ
  Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001 Mar 15;19(6):1759-67.
•   Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG
  Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999 Sep;17(9):2971-94. Erratum in: J Clin Oncol 2000 Aug;18(16):3064. J Clin Oncol 1999 Dec;17(12):3860.
•   Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH
  On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996 Feb;7(2):189-95.
•   Herrington JD, Kwan P, Young RR, Lagow E, Lagrone L, Riggs MW
  Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. Pharmacotherapy. 2000 Nov;20(11):1318-23.
•   Laszlo J
  Nausea and vomiting as major complications of cancer chemotherapy. Drugs. 1983 Feb;25 Suppl 1:1-7.
•   Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT
  Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992 Oct;1(5):331-40.
•   Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ
  Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999 Jan 21;340(3):190-5.
•   Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J
  Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer. 1997 Jul;5(4):307-13.
•   Osowski CL, Dix SP, Lynn M, Davidson T, Cohen L, Miyahara T, Sexauer MC, Joyce R, Yeager A, Wingard JR
  An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. Support Care Cancer. 1998 Nov;6(6):511-7.
•   Oyama H, Kaneda M, Katsumata N, Akechi T, Ohsuga M
  Using the bedside wellness system during chemotherapy decreases fatigue and emesis in cancer patients. J Med Syst. 2000 Jun;24(3):173-82.
•   Schwartzberg LS
  Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology (Williston Park). 2007 Jul;21(8):946-53; discussion 954, 959, 962 passim. Review.
•   Shen J, Wenger N, Glaspy J, Hays RD, Albert PS, Choi C, Shekelle PG
  Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA. 2000 Dec 6;284(21):2755-61.
•   Sigsgaard T, Herrstedt J, Handberg J, Kjaer M, Dombernowsky P
  Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol. 2001 Apr 1;19(7):2091-7.
•   Treish I, Shord S, Valgus J, Harvey D, Nagy J, Stegal J, Lindley C
  Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy. Support Care Cancer. 2003 Aug;11(8):516-21. Epub 2003 Jun 27.
•   Wickham R
  Evolving treatment paradigms for chemotherapy-induced nausea and vomiting. Cancer Control. 2012 Apr;19(2 Suppl):3-9. Review.

Randomized Single-Blind Study of Nometex as an Adjunct to Standard Anti-emetics in Ovarian and Advanced Endometrial and Cervical Cancer Patients Who Receive Moderately to Highly Emetogenic Chemotherapy

Details for clinical trial NCT01980160